Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
Date:3/4/2008

vailable in the

U.S.

-- IPLEX(TM)

-- Made IPLEX(TM) available to physicians in Italy at the request of

the Italian Ministry of Health to treat patients with Amyotrophic

Lateral Sclerosis ("ALS"), also known as Lou Gehrig's Disease,

through an expanded access program ("EAP"), with the Company

receiving cost recovery payments for IPLEX(TM) from the Italian

Health Authorities. EAP currently includes 15 physicians and

approximately 70 subjects, and the Company received cost recovery

of $5.4 million for IPLEX(TM) supplied to the EAP in the full-year

2007;

-- Announced positive results from a Phase 2 investigator-sponsored

study of IPLEX(TM) in six patients with myotonic muscular

dystrophy ("MMD") that met the primary study endpoints of being

safe and well-tolerated, and indicated improvements in patients'

muscle mass, cholesterol and triglycerides;

-- Initiated a 24-week, multi-center, randomized, double blind,

placebo-controlled Phase 3 enabling clinical trial with IPLEX(TM)

in 60 patients with MMD;

-- Awarded a grant of $2.1 million from the Muscular Dystrophy

Association ("MDA"), which is expected to cover a substantial

portion of the external costs associated with the MMD trial;

-- Granted Orphan Drug designation for IPLEX(TM) for the treatment of

MMD by the FDA, providing the Company with, among other important

benefits, seven years of market exclusivity upon approval of

IPLEX(TM) for the MMD indication; and

-- Completed an external assessment of the total market for MMD

treatments that indicated that the market for MMD could be as high

as between $800 million and $1.4 billion.

"We
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
2. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
3. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed to Appeal Delisting Notification From Nasdaq
6. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
7. Insmed Appoints Dennis M. Lanfear to Board Of Directors
8. Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
9. Vermillion Announces Effectiveness of Reverse Stock Split
10. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
11. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... measuring vibrational motion of a single molecule with a ... a single molecule differs from the behaviour of larger ... the University of California, Irvine, where post-doctoral researcher Eero ... visiting fellow under professor Vartkess A. Apkarian, whose team ... by Professor Eric O. Potma. The results of the ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... is being held on October 29-30 in San Francisco, ... industry, academic and government researchers and clinicians focused on ... space. , In the twelve years since the ... therapies have been introduced with pharmacogenetic information in the ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 ... released today including improvements to the enterprise replication ... connectors for Lucene, SOLR and Elasticsearch. This release ... this high performance triplestore – GraphDB™ was formerly ... in deploying the only mature enterprise resilient RDF ...
(Date:8/19/2014)... Cellgen Diagnostics today ... fund a corporate lab for its genetic-based medical ... is a critical component in the move from ... implementation of personalized medicine – a more predictive, ... Indiegogo contributions will support Cellgen’s intent to develop ...
Breaking Biology Technology:Seeing a molecule breathe 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... HUBBARD, Ohio, April 8, 2008 NanoLogix, Inc.,(OTC ... 2007 financial data and a director appointment., ... were,reduced by 42% over 2006, while funding for ... information can be accessed at:, http://www.nanologixinc.com/financials.html , ...
... 8, 2008 Raven,biotechnologies, inc., a privately held ... antibody therapeutics (MAbs) for cancer,announced today that it ... under which Monogram will evaluate selected Raven,monoclonal antibodies ... cancer., "Raven,s extensive library of antibody candidates ...
... - The PerOs team is proud to announce,the ... the production,of bacterins as well as an autogenous ... (Oralject(TM))., "The approval of our manufacturing facility ... States marks a significant milestone for,our Company, and ...
Cached Biology Technology:NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director 2Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies 2PerOs obtains USDA Establishment and Product Licenses for it's oral vaccine formulations 2
(Date:8/21/2014)... study aimed at improving the food intake, health and ... homes is among three projects at the University of ... the Canadian Institutes of Health Research (CIHR). , ... Sciences at Waterloo, and a Schlegel research chair in ... to investigate why many Canadians living in long-term care ...
(Date:8/21/2014)... Wednesday, Oct. 18-22, 2014 , WHERE: , ... San Diego, CA 92101 , WHAT: , ... of the latest research in human genetics. Examples ... high-scoring abstracts on rare genetic variants in health ... treatment for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 ...
(Date:8/21/2014)... a novel and versatile modeling strategy to simulate polyelectrolyte ... as well as for studying polyelectrolytes, including DNA and ... much larger and more complex polyelectrolyte systems, and to ... author of a paper on the work and a ... and Engineering. "This is a big step forward for ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell ... the March 2010 issue of Leukemia & Lymphoma. Traditionally ... Lymphoma has agreed to make this report available to the ... of the 2009 MCL Consortium Workshop. "It is gratifying ...
... Resistant wheat plants stave off attacks by Hessian fly larvae ... absorb nutrients, according to a study by Purdue University and ... - similar to human intestines - were observed in three ... function. Those that were given nothing to eat showed no ...
... Allergies and Infectious Diseases (NIAID), part of the National ... totaling $15,254,919 to Tulane University for its ongoing efforts ... viral disease that threatens hundreds of thousands of people ... potential bioterrorism threat. The contract will include collaboration ...
Cached Biology News:Resistant wheat goes for the gut to protect against Hessian flies 2Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2
... kit contains 5 ml CELLection Dynabeads (4.5 ... the human epithelial antigen EpCAM and DNase ... log enrichment of epithelial tumour cells directly ... cells clumps can be enriched from bone ...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
Human PDGF R beta MAb (Clone # PR7212)...
... Ambion's ActivePro In Vitro ... an E.coli lysate, synthesizes ... as well as proteins ... than competing kits. This ...
Biology Products: